Synapse Open Synapse
Biology

Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

BioPharma Dive · · 2 min read

The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

Latest from BioPharma Dive